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Abstract
Background: New Zealand initiated HPV vaccination in 2008, and has attained 3-dose coverage of ~50 % in 12–13
year old girls. Due to the success of program initiatives in Māori girls, higher coverage rates of ~60 % have been
achieved in this group. We have previously reported a benchmark overall pre-vaccination prevalence of oncogenic
HPV infection in high grade cervical lesions in New Zealand. The current extended analysis provides separate
pre-vaccination benchmark prevalence for Māori and non-Māori women.
Methods: The National Cervical Screening Programme Register (NCSP-R) was used to identify any woman aged
20–69 years of age with an index high grade cytology report from 2009–2011. Extended recruitment was
performed until 2012 in clinics with a high proportion of Māori women. Ethnicity status was based on self-reported
information by participating women through phone contact supplemented by recordings on the study
questionnaire (the NCSP-R was not used to extract ethnicity status). A total of 730 women consented to participate
and had a valid HPV test result; 418 of these had histologically-confirmed cervical intraepithelial neoplasia (CIN) 2/3
lesions (149 Māori, 269 non-Māori). The prevalence of any cervical oncogenic HPV infection, HPV16, and HPV18 was
calculated in women with CIN2/3.
Results: In confirmed CIN2/3, the prevalence of any oncogenic HPV, HPV16 and HPV18 was 96 % (95 % CI:91–
99 %), 54 % (95 % CI:46–63 %), 11 % (95 % CI:7–18 %) in Māori and 96 % (95 % CI:93–98 %), 54 % (95 % CI:48–
60 %), 11 % (95 % CI:7–15 %) in non-Māori women, respectively. Age-specific patterns of infection for HPV16/18 in
confirmed CIN2/3 differed between the two groups (Pinteraction = 0.02), with a lower prevalence in younger vs. older
Māori women (57 % in 20–29 years vs 75 % in 40–69 years) but a higher prevalence in younger vs. older non-Māori
women (70 % in 20–29 years vs 49 % in
40–69 years); the difference in the age-specific patterns of infection for HPV16/18 was not significant either when
considering confirmed CIN2 alone (p = 0.09) or CIN3 alone (p = 0.22).
Conclusions: The overall prevalence of vaccine-included types in CIN2/3 was similar in Māori and non-Māori
women, implying that the long-term effects of vaccination will be similar in the two groups.
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Background
New Zealand initiated a national Human Papillomavirus
(HPV) Immunisation Programme in 2008, which involved
routine vaccination of girls aged 12–13 years from 2009
using the quadrivalent HPV6/11/16/18 vaccine, adminis-
tered through a predominantly school-based immunisation
program. Vaccination is also available to girls and young
women up to their 18th birthday through family doctors,
local health centres and some Family Planning clinics [1, 2].
The reported overall population 3-dose coverage rate for
girls aged 12–13 years has been stable at ~50 % since the
immunisation program was introduced. However, a higher
coverage rate has been achieved in Māori compared to
non-Māori and non-Pacific girls (60 vs 50 % as of February
2014, in girls born in 2000) [3]: this was due to the success
of specific program initiatives, which included engagement
with Māori and Pacific stakeholders nationally and region-
ally, the involvement of Māori and Pacific Equity Advisory
Groups to guide the design and roll out of the immunisa-
tion program at the regional level, and the use of the exist-
ing evidence-base to identify service delivery processes
most effective for Māori and Pacific young women [4].
In New Zealand, Māori women currently experience
double the rates of cervical cancer incidence and mor-
tality compared to non-Māori women - in 2010, the
age-standardised cervical cancer incidence and mortal-
ity rates in Māori women were 12.3 and 3.2 per 100,000
women, respectively, whereas the corresponding rates
in non-Māori women were 6.3 and 1.6 per 100,000
women, respectively [5]. A major factor likely to under-
lie this difference in cancer rates is screening behaviour,
and although recent screening program initiatives have
been ‘closing the gap’; recent (2012) 3-yearly screening
coverage rates for women aged 25–69 years in Māori
and non-Māori women have been reported as 61.6 and
83.5 %, respectively [6].
A baseline measure of HPV infection in high grade cer-
vical lesions will provide an important additional measure
of the burden of high grade precancerous disease which
can be substantially reduced via HPV vaccination in
Māori women. We have previously reported the overall
population prevalence of pre-vaccination oncogenic HPV
infection in New Zealand in both high grade cytology and
histologically-confirmed high grade lesions (cervical
intraepithelial neoplasia [CIN] 2/3), in a sample of women
identified via the New Zealand National Cervical Screen-
ing Programme (NCSP) [7]. In the current study we
present findings from an updated analysis, including re-
sults from a new sample of Māori women recruited to the
study. The overall aims of the current study were: (1) to
compare pre-vaccination type-specific HPV prevalence in
high grade disease in Māori and non-Māori women (in-
cluding rates in all women with high grade cytology and
in the subset of these that were histologically-confirmed
CIN2/3 lesions), and (2) to assess whether the prevalence
differed by age group and HPV type in CIN2/3 lesions in
Māori and non- Māori women.
Methods
Study sample and recruitment
The initial phase of the study recruited women with a high
grade cytology report occurring between August 2009 and
February 2011. For the current extended analysis, the
recruitment period was continued to June 2012, with the
extended recruitment period focusing on recruiting Māori
women only. As such, Māori women were oversampled in
the final study population in order to increase the precision
of estimates of HPV prevalence by ethnicity. The overall
response rate to participate to the study through phone
contact was 63 % (response rate by ethnicity could not be
calculated since the ethnicity information came from the
questionnaire). The study recruitment processes, HPV sam-
ple collection [using either SurePathTM (Becton Dickinson)
or ThinPrepTM (Hologic) liquid based cytology (LBC)] and
processing and genotyping procedures have previously been
described [7]. Briefly, the New Zealand National Cervical
Screening Programme Register (NCSP-R) was used to iden-
tify women aged 20–69 years of age with an incident index
high grade cytology report, classified according to the
Bethesda 2001 New Zealand Modified Cytology Classifica-
tion System (2005) as a cytology prediction of a high grade
squamous lesion (HSIL), atypical squamous cells where
HSIL cannot be excluded (ASC-H), abnormal glandular
cells (AGC), adenocarcinoma in situ (AIS), or cytology sug-
gestive of invasion [8]. The data used from the NCSP-R
related to cytology, histology, HPV testing, colposcopy
exams, the National Health Index number and date of
birth, but not ethnicity status.
A total of 750 women consented to participate in the
study, but the final analysis was restricted to 730 women
aged 20–69 years at the time of their index high grade
cytology test who had a valid HPV genotyping test result.
Of these, 592 (81 %) had been included in the previous
analysis, which did not report results by ethnicity (we
excluded two cases of 594 in a prior analysis: one had a
duplicate record and the other did not have a verified
HPV test record; given the very small numbers, this has
no substantial impact on the prior findings) [7]. For the
current analysis, women were classified as Māori or non-
Māori based on self-reported information by participating
women through phone contact supplemented by record-
ings on the study questionnaire (the NCSP-R was not used
to extract ethnicity status). Women reporting multiple
ethnicities of which one was Māori, were categorised as
Māori women, consistent with classification used by the
New Zealand Ministry of Health [9]. All other women,
including women with unknown ethnicity, were cate-
gorised as non-Māori, as in other prior analyses [10].
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One-third (241 of 730) of the final sample were cate-
gorised as Māori and two-thirds (489 of 730) as non-
Māori. A total of 93 % overall were positive for at least
one HPV type.
HPV genotyping
HPV genotyping was performed on the LBC sample
using the Linear Array genotyping system with PGMY
09/11 primers (Roche Molecular Systems, USA), using
previously described methods [7, 11]. A total of 37 types
of HPV were assessed (6, 11, 16, 18, 26, 31, 33, 35, 39,
40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66,
67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39 and
CP6108) [12]. Due to concerns about cross-reactivity
and in accordance with previous studies [7, 11], samples
were considered positive for HPV type 52 only if they
were also negative for HPV types 33, 35 and 58. HPV
types were categorised for analysis according to the
latest classification in relation to carcinogenicity as
assessed by the International Agency for Research on
Cancer (IARC) [13]; ‘oncogenic HPVs’ included 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59 (group 1 carcino-
gens) and 68 (a group 2A carcinogen).
Histological outcomes
For the current analysis, the histological outcomes were
classified according to SNOMED (1986/93) morphology
categories and based on the most severe disease ranking
reported after the index high grade cytology: in our data,
some women had multiple histological examinations
after the index high grade cytology, mostly within six
month from the index cytology test. For these women, we
used the most severe disease ranking in the SNOMED
diagnostic (morphology M) category observed to classify
histology grade. A proportion of women had histology ini-
tially recorded as ‘CIN2/3’ (M67017) as per an older
SNOMED category that did not differentiate CIN2 from
CIN3. For these cases, we adopted the same convention as
in the NCSP-R, which was to classify these cases as CIN2; a
total of 116 out of 229 CIN2 cases were originally recorded
as ‘CIN2/3’.
Statistical analysis
Comparisons between Māori and non-Māori women were
made in all women with a high grade cytology report and
for histologically-confirmed CIN2/3 lesions with respect to:
1) the type-specific prevalence of oncogenic HPV infection
for each type; and 2) the age-specific prevalence of grouped
HPV types (HPV 16, HPV 16/18, other oncogenic types).
The overall type-specific prevalence (and 95 % confi-
dence intervals) of oncogenic HPV infection was de-
scribed in all women with a high grade cytology report,
as well as the subgroup of women with CIN2/3, and dif-
ferences between Māori and non-Māori women were
assessed using the chi-squared test. The various HPV
type groupings used for analysis included: i) each specific
type of oncogenic HPV infection (regardless of co-
infection with other HPV types); ii) HPV 16 and/or 18,
with or without co-infection with other oncogenic HPV
types; iii) pooled other (non-HPV 16/18) oncogenic
HPV types without co-infection with HPV 16/18; iv)
pooled oncogenic HPV, either single type infection only
or co-infections; and v) any HPV positive, including both
oncogenic and low risk (LR) HPV types.
Women were grouped into one of three age categories
(20–29, 30–39 and 40–69 years) and the age-specific
prevalence of oncogenic HPV types in CIN2/3 lesions was
described. Oncogenic HPV types were grouped using a
hierarchical process into: i) HPV 16 positive (regardless of
co-infection with other oncogenic HPV types); ii) HPV 16
and/or 18 (regardless of co-infection with other oncogenic
HPV types); and iii) other oncogenic HPV types (excluding
co-infection with HPV 16 and/or 18). For vaccine-included
types, we described age-specific infection separately for
HPV 16 and HPV 16 and/or 18.
Bivariable analyses was performed to compare the age-
specific prevalence of grouped oncogenic HPV types by
histology grade (CIN2 only, CIN3 only, CIN2/3) between
Māori and non-Māori women, using the chi-squared
test. The chi-squared test for trend across age categories
was then applied, by histology grade, separately in Māori
and non-Māori women. Multivariable analyses were per-
formed to estimate the likelihood of oncogenic HPV in-
fection, stratified by histology grade, incorporating an
interaction term for ethnicity (Māori, non- Māori) and
age group (20–29, 30–39 and 40–69 years). Analyses
were undertaken using STATA 13 (Cary, NC, USA).
Ethics approval
The study obtained ethics approval from the National
New Zealand Ethics Committee, Cancer Council NSW
Human Research Ethics Committee, Australia, and the




Clinical and demographic characteristics of the partici-
pants are described in Table 1. Of the 730 women with
high grade cytology who consented to participate and had
a valid HPV test result, one-third identified as Māori (241
cases). There was a slightly higher proportion of younger
women (20–29 years of age) in the Māori compared to the
non-Māori group (50 vs 44 %). The proportion of women
with histologically-confirmed CIN2/3 lesions in Māori and
non-Māori women were 62 and 55 %, respectively. A total
of 96 % of confirmed CIN2+ lesions were associated with
any HPV positivity.
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Type-specific prevalence of oncogenic HPV infection
Table 2 describes the type-specific prevalence of onco-
genic HPV infection in women with high grade cytology
and Table 3 describes the prevalence in women with
histologically-confirmed CIN 2/3. In both groups, we
identified no difference in the overall infection rates for
all HPV types and for oncogenic HPV between Māori
and non-Māori women. In women with high grade cy-
tology, the infection rates in Māori vs non-Māori women
for all HPV and oncogenic HPV were 95 vs 92 %
(p = 0.14) and 92 vs 87 % (p = 0.08), respectively. In
women with a histologically-confirmed diagnosis of
CIN2/3, the corresponding rates were 96 vs 97 %
(p = 0.57) and 96 vs 96 % (p = 0.37), respectively.
In general, the type-specific prevalence of each onco-
genic HPV infection appeared broadly similar in Māori
and non-Māori women either when considering all
women with high grade cytology or when the group
with histologically confirmed CIN2/3 were considered.
The most common HPV types in women with high
grade cytology in the study (Māori vs non-Māori
women) were HPV 16 (49 vs 43 %), HPV 52 (12 vs
17 %), HPV 31 (14 vs 15 %), HPV 33 (8 vs 12 %) and
HPV 18 (13 vs 11 %). Similarly, the most common HPV
types in CIN 2/3 lesions (Māori vs non-Māori women)
were HPV 16 (54 vs 54 %), HPV 52 (15 vs 20 %), HPV
31 (13 vs 19 %), HPV 33 (10 vs 14 %) and HPV 18 (11
vs 11 %).
The prevalence of HPV 16 and/or 18, regardless of co-
infection with other oncogenic HPV types, did not sig-
nificantly differ between Māori and non-Māori women
either with high grade cytology (59 vs 52 %, p = 0.12) or
with histologically-confirmed high grade disease (62 vs
62 %, p = 0.85). Similarly, the prevalence of other onco-
genic HPV types without co-infection with HPV 16/18
was similar between Māori and non-Māori women
either with high grade cytology (34 vs 35 %, p = 0.28) or
with histologically-confirmed high grade disease (34 vs
34 %, p = 0.85). The overall prevalence of HPV 16 and/
or 18 without co-infection with other oncogenic HPV
types was significantly higher in Māori than non-Māori
women either with high grade cytology (37 vs 24 %,
p = 0.001) or with histologically-confirmed high grade
disease (38 vs 27 %, p = 0.05).
Further details on the type-specific prevalence of
oncogenic HPV infection in women with CIN2 only,
Table 1 Clinical and demographic characteristics of participants (N = 730)
Māori (N=241) Non-Māoria (N=489) Total (N=730)
Characteristics No. (%) No. (%) No. (%) Any HPV positive (%)
Histologically-confirmed CIN 2+ 153 (63) 287 (59) 440 (60) 423 (96)
Cervical cancerb 4 (2) 8 (2) 12 (2) 11 (92)
High grade lesion 149 (62) 269 (55) 418 (57) 404 (97)
CIN 2c 80 (33) 149 (30) 229 (31) 224 (98)
CIN 3 69 (29) 120 (25) 189 (26) 180 (95)
AIS or glandular dysplasia 0 (0) 10 (2) 10 (1) 8 (80)
Histologically-confirmed < CIN 2 75 (31) 186 (38) 261 (36) 232 (89)
Low grade lesion 43 (18) 104 (21) 147 (20) 135 (92)
CIN 1 20 (8) 66 (13) 86 (12) 76 (88)
Other low grade abnormalityd 23 (10) 38 (8) 61 (8) 59 (97)
Negative 32 (13) 82 (17) 114 (16) 97 (85)
Negative/normal 19 (8) 38 (8) 57 (8) 51 (89)
Other non-significant abnormalitye 13 (5) 44 (9) 57 (8) 46 (81)
No biopsy taken/reported 13 (5) 16 (3) 29 (4) 24 (83)
Age 20–29 years 121 (50) 214 (44) 335 (46) 328 (98)
Age 30–39 years 77 (32) 149 (30) 226 (31) 207 (92)
Age 40–69 years 43 (18) 126 (26) 169 (23) 144 (85)
CIN cervical intraepithelial neoplasia, AIS adenocarcinoma in situ
aWomen with unknown ethnicity were categorised as non-Māori
bCervical cancer includes invasive adenocarcinoma, invasive squamous cell carcinoma, microinvasive squamous cell carcinoma, other primary epithelial
malignancy and adenosquamous carcinoma
cIncludes a total of 116 cases initially coded as CIN2/3 (i.e., M67017) in the National Cervical Screening Programme Register (NCSP-R); we re-classified according to
the NCSP-R convention (see text)
dHistological appearance infection with human papillomavirus (HPV), Condyloma acuminatum, Dysplasia/CIN not otherwise specified (NOS)
eInflammation, squamous metaplasia, polyp, other
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CIN3 only, CIN2+ (including AIS or glandular dysplasia
and cancer) and CIN3+ (including AIS or glandular dys-
plasia and cancer) are provided in Supplementary data
(Additional file 1: Tables S1–S4).
Age-specific prevalence of oncogenic HPV infection
The age-specific prevalence of any oncogenic HPV infec-
tion in women with histologically-confirmed high grade
disease was not found to be significantly different be-
tween Māori and non-Māori (Fig. 1). Bivariable analyses
showed that the age-specific prevalence of HPV 16 re-
gardless of co-infection with other HPV types, HPV 16
and/or 18 regardless of co-infection with other HPV
types, or other oncogenic HPV without HPV 16 and/or
18, within each histology grade (CIN 2 only, CIN 3 only,
CIN 2/3) was not statistically different between Māori
and non-Māori women (Table 4).
In general, a significant trend in pooled HPV infection
rates (all types) across age groups was not observed in
Māori women with histologically-confirmed high grade
disease, although younger Māori women tended to have a
lower relative prevalence of HPV 16 and/or 18 and a higher
prevalence of other oncogenic HPV types compared to
older Māori women. In CIN2/3 lesions, the prevalence of
HPV 16/18 in younger (20–29 years) vs. older (40–69
years) Māori women was 57 and 75 %, respectively; the
prevalence of other oncogenic HPV types in younger vs
older Māori women was 42 and 25 %, respectively. In CIN2
lesions only, the prevalence of HPV 16/18 in younger vs.
older Māori women was 51 and 75 %, respectively; the
prevalence of other oncogenic HPV types in younger vs
older was 47 and 25 %, respectively. In CIN3 only, the
prevalence of HPV 16/18 in younger vs. older Māori
women was 65 and 75 %, respectively; the prevalence of
other oncogenic HPV types was 35 and 25 %, respectively.
Table 2 Type-specific prevalence of oncogenic HPV infection in all women with an index high grade cytology
High grade cytology (ASC-H/HSIL/AGC/AIS)
Māori (N=241) Non-Māori (N=489) Overall (N=730)
HR HPV type N % 95 % CI N % 95 % CI N % 95 % CI
HPV16 (any) 119 49 (43–56) 208 43 (38–47) 327 45 (41–48)
HPV52 (any) 29 12 (8–17) 84 17 (14–21) 113 15 (13–18)
HPV31 (any) 33 14 (10–19) 75 15 (12–19) 108 15 (12–18)
HPV33 (any) 20 8 (5–13) 58 12 (9–15) 78 11 (9–13)
HPV18 (any) 31 13 (9–18) 54 11 (8–14) 85 12 (9–14)
HPV58 (any) 22 9 (6–13) 53 11 (8–14) 75 10 (8–13)
HPV51 (any) 21 9 (6–13) 43 9 (6–12) 64 9 (7–11)
HPV39 (any) 16 7 (4–11) 33 7 (5–9) 49 7 (5–9)
HPV45 (any) 9 4 (2–7) 24 5 (3–7) 33 5 (3–6)
HPV59 (any) 12 5 (3–9) 23 5 (3–7) 35 5 (3–7)
HPV35 (any) 9 4 (2–7) 18 4 (2–6) 27 4 (3–5)
HPV56 (any) 12 5 (3–9) 12 3 (1–4) 24 3 (2–5)
HPV68 (any) 1 0 (0–2) 15 3 (2–5) 16 2 (1–4)
HPV16 and/or 18 (any) 141 59 (52–65) 252 52 (47–56) 393 54 (50–57)
HPV16 with HPV18 (any) 9 4 (2–7) 9 2 (1–4) 18 3 (2–4)
HPV16 without HPV18 (any) 110 46 (39–52) 199 41 (36–45) 309 42 (39–46)
HPV18 without HPV16 (any) 22 9 (6–13) 44 9 (7–12) 66 9 (7–11)
HPV16 and/or 18 (without OHR) 88 37 (30–43) 115 24 (20–28) 203 28 (25–31)
HPV16 and/or 18 (with OHR) 53 22 (17–28) 137 28 (24–32) 190 26 (23–29)
OHR without HPV 16/18 82 34 (28–40) 171 35 (31–39) 253 35 (31–38)
HR HPV (single infection) 137 57 (50–63) 212 43 (39–48) 349 48 (44–52)
HR HPV (any) 222 92 (88–95) 423 87 (83–89) 645 88 (86–91)
HPV positive (including LR HPV) 229 95 (91–97) 450 92 (89–94) 679 93 (91–95)
HR high risk, LR low risk, OHR Other high risk, excluding HPV 16 or 18; any – regardless of co-infection with other HPV types
HR HPV includes infection with either type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68
P values for differences were not calculated for each specific HPV type between Māori and non-Māori women due to sample size limitations and concerns about
multiple comparisons
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The prevalence of HPV 16, regardless of co-infection with
other oncogenic HPV types, in younger vs. older Māori
women with CIN2/3, CIN2 and CIN3 was 55 vs 58 %, 49
vs 63 % and 62 vs 50 %, respectively (Table 4). In Māori
women with histologically-confirmed CIN 2/3, the preva-
lence of single infection for any oncogenic HPV did not
change substantially with age (53 % in 20–29 years vs 60 %
in 40–69 years; p = 0.27). But as women became older, the
prevalence of HPV 16 and/or 18 alone (i.e., without co-
infection with other oncogenic HPV types) sharply
increased from 30 % (20–29 years) to 50 % (40–69 years)
(p = 0.03), and the prevalence of other oncogenic HPV
infection alone (i.e., without HPV 16/18) decreased
substantially from 42 % (20–29 years) to 25 % (40–69
years; p = 0.09) (Additional file 1: Figure S1).
By contrast, younger non-Māori women had a higher
relative prevalence of HPV 16 and/or 18 and a lower preva-
lence of other oncogenic HPV types, compared to older
non-Māori women. In CIN2/3 lesions, younger non-Māori
women, compared to older non-Māori women, had a sig-
nificantly higher prevalence of HPV 16 and/or 18 (70 % in
20–29 years vs 49 % in 40–69 years, p = 0.02); the preva-
lence of other oncogenic HPV types was significantly lower
in younger non-Māori women (28 % in 20–29 years vs
43 % in 40–69 years, p = 0.02). In CIN2 lesions only, no sig-
nificant trend in the prevalence of grouped oncogenic HPV
by age categories was observed in non-Māori women; the
prevalence of HPV 16/18 in younger vs. older Māori
women was 63 and 46 %, respectively, and the prevalence
of other oncogenic HPV types in younger vs older was 34
and 50 %, respectively. In CIN3 only, younger non-Māori
women had a significantly higher prevalence of HPV 16
and/or 18 (79 % in 20–29 years vs 52 % in 40–69 years,
p = 0.05); the prevalence of other oncogenic HPV types was
not significantly different by age categories (21 % in 20–29
years vs 33 % in 40–69 years). The prevalence of HPV 16,
Table 3 Type-specific prevalence of oncogenic HPV infection in women with histologically-confirmed CIN 2/3
CIN2/3 combined (N = 418)
Māori (N=149) Non-Māori (N=269) Overall (N=418)
HR HPV type N % 95 % CI N % 95 % CI N % 95 % CI
HPV16 (any) 81 54 (46–63) 146 54 (48–60) 227 54 (49–59)
HPV52 (any) 22 15 (10–21) 53 20 (15–25) 75 18 (14–22)
HPV31 (any) 19 13 (8–19) 52 19 (15–25) 71 17 (14–21)
HPV33 (any) 15 10 (6–16) 38 14 (10–19) 53 13 (10–16)
HPV18 (any) 17 11 (7–18) 29 11 (7–15) 46 11 (8–14)
HPV58 (any) 16 11 (6–17) 36 13 (10–18) 52 12 (9–16)
HPV51 (any) 15 10 (6–16) 26 10 (6–14) 41 10 (7–13)
HPV39 (any) 12 8 (4–14) 19 7 (4–11) 31 7 (5–10)
HPV45 (any) 6 4 (2–9) 13 5 (3–8) 19 5 (3–7)
HPV59 (any) 9 6 (3–11) 13 5 (3–8) 22 5 (3–8)
HPV35 (any) 6 4 (2–9) 11 4 (2–7) 17 4 (2–6)
HPV56 (any) 8 5 (2–10) 4 2 (0–4) 12 3 (2–5)
HPV68 (any) 1 1 (0–4) 9 3 (2–6) 10 2 (1–4)
HPV16 and/or 18 (any) 92 62 (53–70) 167 62 (56–68) 259 62 (57–67)
HPV16 with HPV18 (any) 6 4 (2–9) 7 3 (1–5) 13 3 (2–5)
HPV16 without HPV18 (any) 75 50 (42–59) 139 52 (46–58) 214 51 (46–56)
HPV18 without HPV16 (any) 11 7 (4–13) 21 8 (5–12) 32 8 (5–11)
HPV16 and/or 18 (without OHR) 56 38 (30–46) 72 27 (22–32) 128 31 (26–35)
HPV16 and/or 18 (with OHR) 36 24 (18–32) 95 35 (30–41) 131 31 (27–36)
OHR without HPV 16/18 51 34 (27–42) 92 34 (29–40) 143 34 (30–39)
HR HPV (single infection) 85 57 (49–65) 123 46 (40–52) 208 50 (45–55)
HR HPV (any) 143 96 (91–99) 258 96 (93–98) 401 96 (94–98)
HPV positive (including LR HPV) 143 96 (91–99) 261 97 (94–99) 404 97 (94–98)
HR high risk, LR low risk, OHR Other high risk, excluding HPV 16 or 18; any – regardless of co-infection with other HPV types
HR HPV includes infection with either type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68
P values for differences were not calculated for each specific HPV type between Māori and non-Māori women due to sample size limitations and concerns about
multiple comparisons
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regardless of co-infection with other oncogenic HPV types,
in younger vs. older non-Māori women with CIN2/3, CIN2
and CIN3 was 62 vs 39 % (p = 0.01), 55 vs 43 % (p = 0.26)
and 71 vs 33 % (p = 0.01), respectively (Table 4). In non-
Māori women with histologically-confirmed CIN 2/3, the
prevalence of other oncogenic HPV regardless of co-
infection with HPV 16 and/or 18 was similar at each age
group (~70 %). As women became older, the prevalence of
co-infection between other oncogenic HPV types and HPV
16 and/or 18 decreased from 70 % (20–29 years) to 49 %
(40–69 years) (p = 0.02) as the infection for HPV 16 and/or
18 alone became slightly less prevalent (from 29 % in 20–
29 years down to 22 % in 40–69 years) (Additional file 1:
Figure S1).
The apparent contrasting age-specific pattern of in-
fection for HPV 16 and/or 18 between the two ethnic
groups (i.e., a lower prevalence in younger vs. older




Fig. 1 Age-specific prevalence of oncogenic HPV types by histology grade and ethnicity. Any HR HPV – any high risk (HR) HPV infection,
regardless of co-infection with other HPV types; Any HPV 16 - HPV 16 infection, regardless of co-infection with other oncogenic HPV types; Any
HPV 16 and/or 18 - HPV 16 and/or 18 infection, regardless of co-infection with other oncogenic HPV types; Other HR HPV alone - other high risk
HPV infection without co-infection with HPV 16 and/or 18
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Table 4 Age-specific prevalence of grouped HPV types by histology grade
CIN 2 (N = 229) CIN 3 (N = 189) CIN 2/3 combined (N = 418)
Māori Non-Māori X2 testb Māori Non-Māori X2 testb Māori Non-Māori X2 testb
HR HPV Age group Na % (95 % CI) Na % (95 % CI) P value Na % (95 % CI) Na % (95 % CI) P value Na % (95 % CI) Na % (95 % CI) P value
HPV 16 (any) 20–29 43 49 (33–65) 67 55 (43–67) 0.51 34 62 (44–78) 58 71 (57–82) 0.38 77 55 (43–66) 125 62 (53–71) 0.27
30–39 21 52 (30–74) 54 48 (34–62) 0.74 27 52 (32–71) 41 56 (40–72) 0.73 48 52 (37–67) 95 52 (41–62) 0.95
40–69 16 63 (35–85) 28 43 (24–63) 0.21 8 50 (16–84) 21 33 (15–57) 0.41 24 58 (37–78) 49 39 (25–54) 0.11
Test for trend c P = 0.37 P = 0.26 – P = 0.56 P = 0.01 – P = 0.75 P = 0.01 –
HPV 16 and/or 20–29 43 51 (35–67) 67 63 (50–74) 0.49 34 65 (46–80) 58 79 (67–89) 0.12 77 57 (45–68) 125 70 (62–78) 0.16
18 (any) 30–39 21 62 (38–82) 54 57 (43–71) 0.05 27 63 (42–81) 41 59 (42–74) 0.88 48 63 (47–76) 95 58 (47–68) 0.21
40–69 16 75 (48–93) 28 46 (28–66) 0.17 8 75 (35–97) 21 52 (30–74) 0.46 24 75 (53–90) 49 49 (34–64) 0.08
Test for trend c P = 0.09 P = 0.17 – P = 0.51 P = 0.05 – P = 0.09 P = 0.02 –
OHR without 20–29 43 47 (31–62) 67 34 (23–47) 0.40 34 35 (20–54) 58 21 (11–33) 0.12 77 42 (30–53) 125 28 (20–37) 0.12
HPV 16/18 30–39 21 29 (11–52) 54 43 (29–57) 0.05 27 26 (11–46) 41 32 (18–48) 0.88 48 27 (15–42) 95 38 (28–48) 0.21
40–69 16 25 (7–52) 28 50 (31–69) 0.17 8 25 (3–65) 21 33 (15–57) 0.55 24 25 (10–47) 49 43 (29–58) 0.11
Test for trend c P = 0.09 P = 0.12 – P = 0.51 P = 0.1 – P = 0.09 P = 0.02 –
HR high risk, OHR Other high risk, excluding HPV 16 or 18; any – regardless of co-infection with other HPV types
HR HPV includes infection with either type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68
aTotal number of women at each age group by ethnicity (i.e., including women HPV negative)
bChi-square test for difference between Māori and non-Māori women in the age-specific prevalence of grouped HPV types













older non-Māori women) was significant in a multi-
variable analysis for CIN2/3 lesions (p = 0.02), but not
for CIN2 alone (p = 0.09) or CIN3 alone (p = 0.22),
separately. Similarly, the inverse age-specific pattern
of infection for other oncogenic HPV between the two
ethnic groups (i.e., a relatively higher prevalence in
younger vs. older Māori women and a relatively lower
prevalence of younger vs. older non-Māori women)
was significant for CIN2/3 lesions (p = 0.02), but not
CIN2 alone (p = 0.07) or CIN3 alone (p = 0.27). The ef-
fect of age group on the likelihood of having infection
for HPV 16 only did not significantly differ between
Māori and non-Māori women in high grade lesions
(Table 5).
Further details on the age-specific prevalence of
grouped oncogenic HPV infection in women with high
grade cytology, CIN2+ (including AIS or glandular dyspla-
sia and cancer) and CIN3+ (including AIS or glandular
dysplasia and cancer) are provided in Additional file 1:
Figure S2, Table S5 and Table S6.
Discussion
This is the first study to estimate the type-specific preva-
lence of oncogenic HPV infection according to ethnicity
in New Zealand, and it also represents one of the most ex-
tensive analyses in any setting of the prevalence of onco-
genic HPV infection in histologically-confirmed high
grade lesions. The study was conducted at the onset of the
HPV Immunisation Programme in New Zealand, and thus
provides a benchmark for pre-vaccination type-specific
HPV prevalence rates in high grade lesions in Māori and
non-Māori women. We found no difference in the overall
rate of oncogenic HPV infections, or the rate of HPV 16/
18 infections, between Māori and non-Māori women in
high grade disease. We found that HPV 16 and/or 18 was
present in 62 % of histologically-confirmed CIN2/3 lesions
overall, for both Māori and non-Māori women. However
we did identify a possible contrasting age-specific pattern
of infection for HPV 16/18 in confirmed CIN2/3 lesions
between the two ethnic groups, such that there was a rela-
tively lower prevalence in younger vs. older Māori women
and a higher prevalence in younger vs. older non-Māori
women; although this difference was not borne out when
CIN2 and CIN3 were considered separately.
Although our findings for an increased relative preva-
lence of HPV16/18 in CIN2/3 from younger, compared
to those from older, non-Māori women is broadly con-
sistent with prior findings from a cohort in Guanacaste,
Costa Rica [14], the interaction identified in the current
study between the age-specific relative prevalence and
ethnicity has not previously been reported. However, al-
though we found a significant interaction between age
and ethnicity in predicting the relative prevalence of
HPV16/18 in CIN 2/3, this pattern for a significantly
different, age-specific effect was not confirmed when
only CIN3 lesions, the most serious grade of precancer,
were compared between ethnic groups. Taken together
therefore, our findings imply that HPV vaccination with
current generation vaccines is expected to have a similar
impact in Māori and non-Māori women in the longer
term. However, there is an ongoing need to prioritise
cervical screening initiatives in Māori as well as other
groups of women in New Zealand (for example Pacific
women), who have historically lower screening participa-
tion rates [6].
Our study has some limitations. It is possible that
women who consented to participate in the study might
differ from those who did not in terms of demographic
characteristics or cervical screening history, which may
have impacted the type-specific rates of HPV in high
grade lesions, and that this difference might vary between
ethnic groups. However, in our previous analysis we
showed that the sample of women consenting to the study
was representative of those with high grade lesions in the
New Zealand NCSP Register [6]. It is possible that signifi-
cant differences between the prevalence of specific HPV
types exist between Māori and non-Māori women; we
were not able to test for this due to sample size limitations
and concerns about multiple comparisons. Therefore, we
have focused here mainly on our findings for the main
groups of relevant HPV types (i.e., HPV 16/18 [the vaccine
included oncogenic types] and all other oncogenic types
considered as a group). It is also possible that we did not
detect an interaction between age and ethnicity for specific
lesion grades because of a lack of power to detect such an
interaction. Note also that we did not control for
deprivation or other factors potentially underlying our
findings for Māori vs. non-Māori women. The primary
aim of the study was to describe potential differences in
type-specific HPV prevalence by ethnicity, rather than ex-
plore mechanisms that underlie ethnic differences in the
prevalence. The importance of doing so is that in New
Zealand targeted programs are implemented for specific
ethnic groups (irrespective of deprivation). We have there-
fore configured the analysis to be directly relevant to this
approach.
In line with our previous analysis [7], the very high
(96 %) overall oncogenic HPV infection rate we observed
in confirmed CIN2/3 lesions appears to be somewhat
higher than reported in other studies and regions; possible
reasons include improvements in PCR technology used to
detect and genotype HPV infection [12] as well as our
concentrated recruitment of an ‘enriched’ population of
women who had both high grade cytology and a subse-
quently confirmed high grade CIN (by contrast, many
prior studies of HPV prevalence in CIN2/3 have tested
samples identified via laboratory reports of CIN2/3 for
which biopsy may have been originally performed for a
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Table 5 Likelihood of having grouped HPV infection in HPV positive women with histologically confirmed high grade lesion at each level of age group by ethnicity
Category Any HPV 16 positivea Any HPV 16 and/or 18 positivea Other HR HPV without HPV 16 and/or 18
CIN 2 CIN 3 CIN 2/3 CIN 2 CIN 3 CIN 2/3 CIN 2 CIN 3 CIN 2/3
OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
Non-Māori, 20–29 years 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Non-Māori, 30–39 years 0.8 (0.4–1.5) 0.5 (0.2–1.2) 0.6 (0.4–1.1) 0.8 (0.4–1.6) 0.5 (0.2–1.2) 0.6 (0.4–1.1) 1.4 (0.7–2.9) 2.1 (0.8–5.2) 1.7 (0.9–3.0)
Non-Māori, 40–69 years 0.6 (0.3–1.5) 0.2 (0.1–0.6) 0.4 (0.2–0.8) 0.5 (0.2–1.3) 0.4 (0.1–1.1) 0.4 (0.2–0.9) 2.0 (0.8–5.0) 2.2 (0.7–6.9) 2.1 (1.1–4.3)
Māori, 20–29 years 0.8 (0.4–1.7) 0.7 (0.3–1.6) 0.7 (0.4–1.3) 0.6 (0.3–1.4) 0.5 (0.2–1.2) 0.6 (0.3–1.0) 1.7 (0.8–3.7) 2.1 (0.8–5.4) 1.8 (1.0–3.4)
Māori, 30–39 years 0.9 (0.3–2.4) 0.4 (0.2–1.1) 0.7 (0.3–1.3) 1.2 (0.4–3.7) 0.6 (0.2–1.9) 0.9 (0.4–2.0) 0.9 (0.3–2.6) 1.6 (0.5–4.7) 1.1 (0.5–2.4)
Māori, 40–69 years 1.4 (0.4–4.1) 0.4 (0.1–1.9) 0.8 (0.3–2.1) 1.7 (0.5–5.9) 0.8 (0.1–4.4) 1.2 (0.5–3.3) 0.6 (0.2–2.2) 1.3 (0.2–7.1) 0.8 (0.3–2.3)
Test for interactionb P = 0.36 P = 0.52 P = 0.16 P = 0.09 P = 0.22 P = 0.02 P = 0.07 P = 0.27 P = 0.02
Other HR HPV types include infection with either type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68, not 16 or 18
aRegardless of co-infection with other HPV types













range of indications) [15]. Despite the use of an enriched
population in our study, the relative prevalence of specific
HPV types in CIN2/3 in the current study is broadly
consistent with results from a recent meta-analysis of inter-
national studies [16]. The most common HPV types
detected in CIN2/3 lesions in the current analysis and meta-
analysis of other international studies were, respectively,
HPV 16 (54 vs 53 %), HPV 52 (18 vs 12 %), HPV 31 (17 vs
12 %), HPV 33 (13 vs 9 %) and HPV 18 (11 vs 8 %) [16].
It is known that type-specific prevalence of HPV varies
substantially by geographical regions [16, 17]. However, glo-
bally, relatively little data are available on comparative type-
specific HPV prevalence by ethnicity when a sample of
women are drawn from the same geographical area over the
same period, especially in women with high grade lesions.
We identified one recent US study, which found a significant
difference (p < 0.0001) in the prevalence of HPV 16/18 by
ethnicity (with or without co-infection with other oncogenic
HPV types) in women 18–39 years of age with CIN2+, after
adjusting for age, diagnosis grade and geographic location
[18]. The prevalence of HPV 16/18 (regardless of co-
infection with other oncogenic HPV types) was the highest
in Non-Hispanic whites (59.1 %) followed by Hispanic
(46.3 %), Asian (43.3 %) and Non-Hispanic black (41.9 %)
women. The adjusted prevalence ratio (APR) of having HPV
16/18 vs other oncogenic HPV types in CIN2+ was signifi-
cantly lower in Non-Hispanic black (APR = 0.70, 95 % CI:
0.62–0.80) and Hispanic women (APR = 0.83, 95 % CI:
0.74–0.93), compared to Non-Hispanic white women, and
the unadjusted prevalence ratio was similar to the APR
[18]. Therefore, the US study identifies the potential for
HPV vaccine impact to vary by ethnic group (in a way that
is independent from, and additional to, the effect of poten-
tially differing coverage between groups).
Although the results of general population HPV preva-
lence studies are not directly comparable with our findings,
we identified two such studies assessing type-specific preva-
lence of HPV by ethnicity or Indigenous status. In Canada,
HPV prevalence was assessed among women with aborigi-
nal, Caucasian and other ethnic backgrounds (81 % of
participants were women with normal cytology) [19]. The
study found that overall HPV prevalence in women <30 years
was similar in Aboriginal and Caucasian women, but in
women aged over 30 years, HPV prevalence was significantly
higher in Aboriginal women. In Australia, type-specific
population prevalence was assessed in Indigenous and non-
Indigenous women 15–40 years of age attending for a rou-
tine Pap smear in the WHINURS study [20]. It was found
that Indigenous and non-Indigenous women 30–40
years of age had a similar infection rate for HPV 16/18,
but Indigenous women had a significantly higher infec-
tion for other oncogenic HPV types (35 vs 22.5 %,
p < 0.001). In women aged 15–29 years, Indigenous and
non-Indigenous women had similar infection rates for
HPV 16/18 and for other oncogenic HPV types. In this
study, a lower prevalence of HPV type 68 was reported in
Indigenous women (0.9 vs 3.2 %, p < 0.001), but the authors
stated that this finding need to be interpreted with caution
given that multiple comparisons of genotype groups were
performed. In general terms, although these studies provide
some basis for concluding that HPV type-specific infection
rates can potentially differ between ethnic groups in the
same population, general population studies are likely to
be more limited in their power to detect differences be-
tween groups because of the lower absolute prevalence of
HPV in the general population compared to the group
with high grade lesions.
Conclusion
Our study, therefore, represents one of the first detailed
investigations of the relative prevalence of vaccine-included
HPV types which can directly compare findings across eth-
nic groups. Our finding that the overall prevalence of
vaccine-included HPV types in CIN2/3 is similar in Māori
and non-Māori women is reassuring, and implies that the
longer term effects of vaccination will be similar in the two
groups, or even (given the higher coverage rates achieved),
that better post-vaccination outcomes might be achieved in
Māori groups. We conclude that ongoing high coverage of
both Māori and non-Māori women in the National HPV
Immunisation Programme in New Zealand is required to
achieve high overall program effectiveness, and our results
also underpin the ongoing importance of initiatives to
further increase participation in cervical screening in Māori
women. In the future, repeat cross-sectional surveys of the
type reported here will provide an ongoing mechanism of
monitoring the impact of HPV vaccination in New
Zealand. To facilitate ongoing monitoring of the impact of
HPV vaccination on the National Cervical Screening Pro-
gram, individual record linkage between the NCSP-R and
immunisation registries is under active discussion.
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